Centers | ||
Therapeutic Accelerator Program (TAP) | Edinburgh Drug Discovery | EU-OPENSCREEN |
Test |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Partnerships |
Events |
Jobs |
Brigham & Woman's Hospital and Sanofi to Partner in Type 1 Diabetes SpaceSanofi and Brigham & Woman's Hospital an affiliate of Harvard University have entered into a joint collaboration to develop new drugs based on novel immunomodulatory approach to treat Type 1 Diabetes. Scientists from both groups will be... View all Pharma and Academia Consortium Partner to Develop New Drugs in EuropeA consortium of academic institutes from Germany, Britain, Netherlands and Denmark partner with a group of leading pharmaceutical companies which include AstraZeneca, Sanofi, Bayer, UCB , Lundbeck , Merck KGaA, and Janssen which is a JNJ... View all GSK and MD Anderson to co-develop new cancer therapeuticsGlaxoSmithkline and MD Anderson Cancer Center entered into a co-development and license agreement to develop antibody based therapeutics to treat cancer. Under this agreement MD Anderson grants exclusive rights to antibodies developed during the... View all |
No EVENTS for listing |
No Job Posts |


